Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALZN002

Cell therapy · Immune activation, directed at amyloid-beta 1-42 · developed by Alzamend Neuro

Phase 1/2 Most advanced trial

ALZN Developer

1 Registered trials

What is ALZN002?

ALZN002 is an autologous dendritic cell therapy pulsed with a mutant amyloid-beta peptide (E22W). It activates CD4+ T cells and B cells to generate anti-amyloid-beta antibodies, reducing amyloid accumulation in the brain. It is studied in Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Targets: amyloid-beta 1-42 (antigen)
Mechanism: Immune activation, directed at amyloid-beta 1-42
Pathways: immune_activation
Therapy area: Neurology
Developer: Alzamend Neuro, Inc. (ALZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05834296	Phase 1/2	Alzheimer Disease	Active not recruiting	ALZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer Disease

More from Alzamend Neuro

Lithium Salicylate Phase 1/2

Sources

ClinicalTrials.gov NCT05834296

Updated Oct 3, 2026. Something wrong or missing? Report it on the ALZN page.

Follow ALZN, the company behind ALZN002

See ALZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z